top of page

PUBLICATIONS

A List of Recent Publications

​

  • Kumar NP, Padmapriyadarsini C, Nancy A, Tamizhselvan M, Mohan A, Reddy D, Devi NP, Rathinam P, Jeyadeepa B, Shandil RK, Guleria R. Effect of Metformin on systemic chemokine responses during anti-tuberculosis chemotherapy. Tuberculosis (Edinb). 2024. 148:102523. https://doi.org/10.1016/j.tube.2024.102523

​

  • Kaur P, V. K. R, C. N. N, K. B, Singh M, Hobbie SN, Shandil RK and Narayanan S. Apramycin kills replicating and non-replicating Mycobacterium tuberculosis. Front Trop Dis. 2024;5:1413211.https://doi.org/10.3389/fitd.2024.1413211

​

  • Kanhed AM, Vora A, Thakkar A, et al. Design and synthesis of diphenyl-1H-imidazole analogs targeting Mpro/3CLpro enzyme of SARS-CoV-2. Med Chem Res. 2024. 33:1568-1577 https://doi.org/10.1007/s00044-024-03263-7

​

​

  • Kotimoole CN, Ramya VK, Kaur P, et al. Discovery of Species-Specific Proteotypic Peptides To Establish a Spectral Library Platform for Identification of Nontuberculosis Mycobacteria from Mass Spectrometry-Based Proteomics. J Proteome Res. 2024. 23(3):1102-1117. https://doi.org/10.1021/acs.jproteome.3c00850

​

​

  • Putri GN, Gudla CS, Singh M, et al. Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV [published online ahead of print, 2023 Nov 7]. Antiviral Res. 2023;105739. https://doi.org/10.1016/j.antiviral.2023.105739 

​

  • Rudramurthy GR, Naveenkumar CN, Bharathkumar K, Shandil RK, Narayanan S. Genomic Mutations in SARS-CoV-2 Genome following Infection in Syrian Golden Hamster and Associated Lung Pathologies. Pathogens. 2023; 12(11):1328. https://doi.org/10.3390/pathogens12111328

​

​

  • Konidala, S. K., Shanmugam S, S., Narayanan, S., Shandil, R., Puram, P. K., Samineni, R., Pulusu, V. S., & Sri, K. H. (2023). Development and Validation of UPLC-MS/MS Method for Simultaneous Determination of Multi-Class Antibiotics, Antivirals and Antifungals in Water. Asian Journal of Chemistry, 35(10), 2509–2516. https://doi.org/10.14233/ajchem.2023.28186

​

  • Varsa S RB, Pandey N, Ghosh A, et al. Mechanosynthesis of Stable Salt Hydrates of Allopurinol with Enhanced Dissolution, Diffusion, and Pharmacokinetics. ACS Omega. 2023;8(37):34120-34133. Published 2023 Sep 7. https://doi.org/10.1021/acsomega.3c05263

​

  • Narayan R, Sharma M, Yadav R, et al. Picolinic acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and influenza A virus in vivo. Cell Rep Med. 2023;101127. https://doi.org/10.1016/j.xcrm.2023.101127

​

  • Rudramurthy G, Shandil R, Narayanan S. In-vitro screening of repurposed drug library against severe acute respiratory syndrome coronavirus-2. Medical Research Archives. 2023;11(2).https://doi.org/10.18103/mra.v11i2.3595

​

  • Mehla R, Kokate P, Bhosale SR, et al. A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters. Vaccines (Basel). 2023;11(2):255. https://doi.org/10.3390/vaccines11020255

​

  • Devkar HU, Thakur NL, Kaur P. Marine-derived antimicrobial molecules from the sponges and their associated bacteria. Can J Microbiol. 2023;69(1):1-16. https://doi.org/10.1139/cjm-2022-0147

​

​

  • Padmapriydarsini C, Mamulwar M, Mohan A, et al. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis. Clin Infect Dis. 2022;75(3):425-434. https://doi.org/10.1093/cid/ciab964

​

​

  • Shandil R K, Dhup S, Narayanan S, Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases Stem Cells International 2022 https://doi.org/10.1155/2022/6379161

​

  • Prabhu P, Fernandes T, Damani M, Chaubey P, Narayanan S, Sawarkar S. 2Receptor Specific Ligand conjugated Nanocarriers: an Effective Strategy for Targeted Therapy of Tuberculosis. Curr Drug Deliv. 2021 Dec 16. https://doi.org/10.2174/1567201819666211216141942  

​

  • Chandrasekaran Padmapriydarsini, Megha Mamulwar, Anant Mohan, Prema Shanmugam, N S Gomathy, Aarti Mane, Urvashi B Singh, Nathella Pavankumar, Abhijeet Kadam, Hemanth kumar, Chandra Suresh, Devaraju Reddy, Poornaganga Devi, P M Ramesh, Lakshmanan Sekar, Shaheed Jawahar, R K Shandil, Manjula Singh, Jaykumar Menon, Randeep Guleria, METRIF Team, Randomized trial of Metformin with Anti-tuberculosis drugs For Early Sputum Conversion in Adults with Pulmonary Tuberculosis, Clinical Infectious Diseases, 2021;  https://doi.org/10.1093/cid/ciab964 

​

  • Kaur P, Potluri V, Ahuja VK, Naveenkumar CN, Krishnamurthy RV, Gangadharaiah ST, Shivarudraiah P, Eswaran S, Nirmal CR, Mahizhaveni B, Dusthackeer A, Mondal R, Batt SM, Richardson EJ, Loman NJ, Besra GS, Shandil RK, Narayanan S. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis (Edinb). 2021 Jun 18;129:102104. https://doi.org/10.1016/j.tube.2021.102104  

 

  • Narayanan S, Shandil RK, Ahuja VK, Shanmugam SS, Mahesh K U H, Ramesh N, Surendran N. Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 1;1174:122714 https://doi.org/10.1016/j.jchromb.2021.122714

 

  • Vijay P, Radha K S, Gavara R, Ganesh S, Brice C, Sergio W and Shridhar N. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malaria Journal. 2020. 19:365 https://doi.org/10.1186/s12936-020-03421-3

 

  • Balachandra B, Radha K S, Jagadeesh B and Tanjore S B. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Applied Sciences. 2020. 10, 5704; https://doi.org/10.3390/app10165704

​

  • Pradeep A S, Neha V S, Seetha S, Pallavi M, Bhavana N, Sushrut D, Sowmya K B, Devaiah M K, Ramya V K, Benudhar M, Priyasha M, Noriko Y, Susanta K G, Radha K S, Shridhar N, Brice C, Kouichi H, Anupkumar R A, Neena V and Varadharajan S. Plasmodium vivax liver stage assay platforms using Indian clinical isolates. Malaria Journal. 2020. 19:214 https://doi.org/10.1186/s12936-020-03284-8

 

  • Richa M, Sakshi K, Nitish M, Parijat B, Mansi M, MohamedHusen M, Vasista , Vijay K A, Radha K , Raju S R, Aswin S N S, Amit S. Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis. Sci. Transl. Med. 2019. 11: eaaw6635.  https://doi.org/10.1126/scitranslmed.aaw6635

 

  • Manjunatha M R,  Radha K S, Manoranjan P, Claire S, Anisha A, Vijender P, Naveen K, Jyothi M, Sreenivasaiah M,Ashwini N, Supreeth G, Sreevalli S, Vasan K S, Vasanthi R, Meenakshi M, Christopher C, Khisi M, Scott B, Ruben T,Pravin S I, Shridhar N, Monalisa C, and Pravin S S. Scaffold Morphing to Identify Novel DprE1 Inhibitors with Antimycobacterial Activity: ACS Med Chem. 2019. https://doi.org/10.1021/acsmedchemlett.9b00343

 

  • Shruthi T G, Eswaran S, Shivarudraiah P, Narayanan S, Subramanian S. Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety. Bioorg Med Chem Lett. 2019. 29(1):97-102. PubMed PMID: 30448235. https://doi.org/10.1016/j.bmcl.2018.11.002

 

  • Tantry S J, Markad S D, Shinde V, Bhat J, Balakrishnan G, et al. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. J Med Chem. 2017. 60 (4):1379-1399. PubMed PMID: 28075132. https://doi.org/10.1021/acs.jmedchem.6b01358

bottom of page